Exhibit 99.1
primage1a02.jpg
Alimera Sciences Reports First Quarter 2017 Financial Results
 
Revenue increased 14% for the first quarter of 2017 compared to the first quarter of 2016
Global end user unit demand increased by 32% in the first quarter of 2017 compared to the first quarter of 2016
Reduction in the first quarter of 2017 operating expenses of approximately $2.7 million compared to the first quarter of 2016 operating expenses
Company to host conference call on May 9, 2017 at 8:00 AM ET
ATLANTA, May 8, 2017 /GLOBENEWSWIRE/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization, research and development of prescription ophthalmic pharmaceuticals, today announced top-line financial results for the three months ended March 31, 2017.
“We are very pleased with the significant increase in end user unit demand seen in the first quarter of 2017. Additionally, our distribution partners made strides to put us in an excellent position for expansion of ILUVIEN availability in our international business,” said Dan Myers, Alimera's Chief Executive Officer. “The presentation of real world data on ILUVIEN this week at the ARVO conference, data that we believe better demonstrates ILUVIEN’s safety and effectiveness than our pivotal FAME Trial, will resonate well with physicians and will have a positive impact on our business. Due to the increase in end user unit demand, anticipated growth and our reduction in operating expenses, we believe we should be able to achieve positive cash flows from operations.”
First Quarter Financial Results
Consolidated net revenue increased by approximately $800,000, or 14%, to approximately $6.6 million for the three months ended March 31, 2017, compared to net revenue of approximately $5.8 million for the three months ended March 31, 2016. The increase was primarily attributable to increased sales volume in the U.S. and our international segment.
U.S. net revenue increased by approximately $300,000, or 7%, to approximately $4.4 million for the three months ended March 31, 2017, compared to U.S. net revenue of approximately $4.1 million for the three months ended March 31, 2016. This increase was driven by increased sales of ILUVIEN in the U.S., attributable to an increase in end user unit demand, offset by fluctuations in the timing of orders by our two U.S. distributors.
International net revenue increased approximately $500,000, or 29%, to approximately $2.2 million for the three months ended March 31, 2017, compared to approximately $1.7 million for the three months ended March 31, 2016. The increase was primarily attributable to higher sales volume in the United Kingdom, Germany and Portugal compared to the first quarter of 2016, offset by decreases in the value of the British pound sterling and the Euro which impacted reported revenue.
Consolidated gross profit increased by $600,000, or 11%, to $6.0 million for three months ended March 31, 2017, compared with $5.4 million for the three months ended March 31, 2016. Gross margin was 91% and 93% for the three months ended March 31, 2017 and 2016, respectively.


The following information was filed by Alimera Sciences Inc (ALIM) on Tuesday, May 9, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Alimera Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alimera Sciences Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account